Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S.; Kumar, S.; Plesner, T.; Goldschmidt, H.; Orlowski, R.; Perrot, A.; Chari, A.; Cook, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Low intake of fruits and vegetables and high intake of processed meats and juices are associated with risk of MGUS in the national health and nutrition examination survey (NHANES) database
    Meeting Abstract

    Joseph, J. M.; Tang, L.; Hillengass, J.; Moysich, K.; Landgren, O.; Usmani, S.; Lesokhin, A. M.; McCann, S. E.; Shah, U. A.
    Blood (2022)

    Fulltext@MSK | Save
  • MajesTEC-7: A phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant
    Meeting Abstract

    Krishnan, A. Y.; Manier, S.; Terpos, E.; Usmani, S.; Khan, J.; Pearson, R.; Girgis, S.; Guo, Y.; McAleer, D.; Olyslager, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the phase 3 MAIA study
    Meeting Abstract

    Kumar, S. K.; Moreau, P.; Bahlis, N. J.; Facon, T.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • An end-of-study subgroup analysis of black patients from the phase 2 griffin study of daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y. A.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A. Z.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: MAIA age subgroup analysis
    Meeting Abstract

    Facon, T.; Kumar, S. K.; Weisel, K.; Usmani, S.; Moreau, P.; Plesner, T.; Orlowski, R. Z.; Bahlis, N. J.; Basu, S.; Nahi, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the griffin and master studies
    Meeting Abstract

    Callander, N.; Silbermann, R.; Kaufman, J. L.; Godby, K. N.; Laubach, J. P.; Schmidt, T. M.; Sborov, D. W.; Medvedova, E.; Reeves, B.; Dhakal, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Geometric network analysis defines poor-prognosis subtypes in multiple myeloma
    Meeting Abstract

    Simhal, A. K.; Maclachlan, K. H.; Elkin, R.; Zhu, J.; Usmani, S.; Keats, J. J.; Norton, L.; Deasy, J. O.; Oh, J. H.; Tannenbaum, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups
    Meeting Abstract

    Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Blood (2022)

    Fulltext@MSK | Save